The Experts below are selected from a list of 243 Experts worldwide ranked by ideXlab platform
Jackie Q Wu - One of the best experts on this subject based on the ideXlab platform.
-
radiotherapy treatment plans with rapidarc for prostate cancer involving Seminal Vesicles and lymph nodes
International Journal of Radiation Oncology Biology Physics, 2010Co-Authors: Jackie Q WuAbstract:Purpose Dosimetric results and treatment delivery efficiency of RapidArc plans to those of conventional intensity-modulated radiotherapy (IMRT) plans were compared using the Eclipse treatment planning system for high-risk prostate cancer. Materials and Methods This study included 10 patients. The primary planning target volume (PTV P ) contained prostate, Seminal Vesicles, and pelvic lymph nodes with a margin. The boost PTV (PTV B ) contained prostate and Seminal Vesicles with a margin. The total prescription dose was 75.6 Gy (46.8 Gy to PTV P and an additional 28.8 Gy to PTV B ; 1.8 Gy/fraction). Three plans were generated for each PTV: Multiple-field IMRT, one-arc RapidArc (1ARC), and two-arc RapidArc (2ARC). Results In the primary IMRT with PTV P , average mean doses to bladder, rectum and small bowel were lower by 5.9%, 7.7% and 4.3%, respectively, than in the primary 1ARC and by 3.6%, 4.8% and 3.1%, respectively, than in the primary 2ARC. In the boost IMRT with PTV B , average mean doses to bladder and rectum were lower by 2.6% and 4.8% than with the boost 1ARC and were higher by 0.6% and 0.2% than with the boost 2ARC. Integral doses were 7% to 9% higher with RapidArc than with IMRT for both primary and boost plans. Treatment delivery time was reduced by 2-7 minutes using RapidArc. Conclusion For PTVs including prostate, Seminal Vesicles, and lymph nodes, IMRT performed better in dose sparing for bladder, rectum, and small bowel than did RapidArc. For PTVs including prostate and Seminal Vesicles, RapidArc with two arcs provided plans comparable to those for IMRT. The treatment delivery is more efficient with RapidArc.
-
radiotherapy treatment plans with rapidarc for prostate cancer involving Seminal Vesicles and lymph nodes
International Journal of Radiation Oncology Biology Physics, 2010Co-Authors: Jackie Q WuAbstract:Purpose Dosimetric results and treatment delivery efficiency of RapidArc plans to those of conventional intensity-modulated radiotherapy (IMRT) plans were compared using the Eclipse treatment planning system for high-risk prostate cancer. Materials and Methods This study included 10 patients. The primary planning target volume (PTV P ) contained prostate, Seminal Vesicles, and pelvic lymph nodes with a margin. The boost PTV (PTV B ) contained prostate and Seminal Vesicles with a margin. The total prescription dose was 75.6 Gy (46.8 Gy to PTV P and an additional 28.8 Gy to PTV B ; 1.8 Gy/fraction). Three plans were generated for each PTV: Multiple-field IMRT, one-arc RapidArc (1ARC), and two-arc RapidArc (2ARC). Results In the primary IMRT with PTV P , average mean doses to bladder, rectum and small bowel were lower by 5.9%, 7.7% and 4.3%, respectively, than in the primary 1ARC and by 3.6%, 4.8% and 3.1%, respectively, than in the primary 2ARC. In the boost IMRT with PTV B , average mean doses to bladder and rectum were lower by 2.6% and 4.8% than with the boost 1ARC and were higher by 0.6% and 0.2% than with the boost 2ARC. Integral doses were 7% to 9% higher with RapidArc than with IMRT for both primary and boost plans. Treatment delivery time was reduced by 2-7 minutes using RapidArc. Conclusion For PTVs including prostate, Seminal Vesicles, and lymph nodes, IMRT performed better in dose sparing for bladder, rectum, and small bowel than did RapidArc. For PTVs including prostate and Seminal Vesicles, RapidArc with two arcs provided plans comparable to those for IMRT. The treatment delivery is more efficient with RapidArc.
James P Wylie - One of the best experts on this subject based on the ideXlab platform.
-
when should the Seminal Vesicles be included in the target volume in prostate radiotherapy
Clinical Oncology, 2007Co-Authors: Neil A Bayman, James P WylieAbstract:External beam radiotherapy to the prostate and Seminal Vesicles as a radical treatment for prostate cancer can result in a significant dose being delivered to the rectum. This can be reduced if the target volume includes the prostate only. Using a Medline search, published studies are reviewed to show that the risk of Seminal vesicle involvement can be accurately predicted using readily available pre-treatment parameters. We recommend when to exclude the Seminal Vesicles from a target volume, and the proportion of Seminal Vesicles that should be included in a target volume in higher risk patients.
L Desnoyers - One of the best experts on this subject based on the ideXlab platform.
-
major proteins of bovine Seminal Vesicles bind to spermatozoa
Biology of Reproduction, 1994Co-Authors: Puttaswamy Manjunath, L Chandonnet, E Leblond, L DesnoyersAbstract:Bovine Seminal Vesicles synthesize a family of closely related proteins, namely BSP-A1, BSP-A2, BSP-A3, and BSP-30-kDa (collectively called BSP proteins). Recently, we showed that these proteins bind specifically to choline phospholipids. Since this class of phospholipids is the major phospholipid fraction of the spermatozoan membrane, we investigated the binding of BSP proteins to spermatozoa. Polyclonal antibodies against purified BSP proteins raised in rabbits were used to detect these antigens in bovine epididymal and ejaculated spermatozoa as well as in bovine Seminal plasma. Comparison of spermatozoa taken from the caudae epididymides with ejaculated spermatozoa through use of various techniques, namely, surface labeling followed by immunoprecipitation and immunoblotting, showed that epididymal spermatozoa are devoid of BSP proteins whereas ejaculated spermatozoa possess membrane-bound BSP proteins. Through use of the indirect immunofluorescence technique, the ejaculated spermatozoa of bull were characterized by an immunoreaction restricted to the midpiece, acrosome, and postacrosomal region, but no specific immunostaining could be found on the surface of epididymal spermatozoa. Surface-labeled BSP proteins on spermatozoa could not be displaced with buffers containing high salt concentration (1 M NaCI), but could be displaced specifically with phosphorylcholine (alone or in combination with urea). The data indicate that the BSP proteins that are secretory products of the Seminal Vesicles bind to the sperm surface upon ejaculation.
Oztug Adsan - One of the best experts on this subject based on the ideXlab platform.
-
A unique scrotal extratesticular epidermod cyst attached to the Seminal Vesicles
Cuaj-canadian Urological Association Journal, 2013Co-Authors: Hasan Salih Sağlam, şukru Kumsar, Osman Köse, Oztug AdsanAbstract:A 46-year old man was admitted with a scrotal long standing painless mass. The work up included physical examination, alpha- fetoprotein (αFP) and beta-human chorionic gonadotropin (β-hCG) analyses, scrotal ultrasound (US), magnetic resonance imaging (MRI) and urethrocystoscopy. The patient underwent surgery. Surgical exploration revealed a separate mass between the testes extending superiorly with a thin stalk. It was dissected easily to the anterior aspect of the Seminal Vesicles and removed from the junction to the Seminal Vesicles. Pathology reported an epidermoid cyst. To our knowledge this is the first case of a scrotal extratesticular epidermoid cyst attached to the Seminal Vesicles. Epidermoid cysts can be seen anywhere in the midline from the cranium to the anus. Embriologically abnormal closure of neural groove or epithelial fusion lines is one of the theories that seem more probable. Genital epidermoid cysts are rare, painless and usually located in the testes. Up to date less than 10 case reports of extratesticular epidermoid cysts have been published. For those cases malignancy may not be ruled out, so the surgical removal was advocated.
-
A unique scrotal extratesticular epidermod cyst attached to the Seminal Vesicles
Cuaj-canadian Urological Association Journal, 2013Co-Authors: Hasan Salih Sağlam, şukru Kumsar, Osman Köse, Oztug AdsanAbstract:A 46-year old man was admitted with a scrotal long standing painless mass. The work up included physical examination, alpha- fetoprotein (αFP) and beta-human chorionic gonadotropin (β-hCG) analyses, scrotal ultrasound (US), magnetic resonance imaging (MRI) and urethrocystoscopy. The patient underwent surgery. Surgical exploration revealed a separate mass between the testes extending superiorly with a thin stalk. It was dissected easily to the anterior aspect of the Seminal Vesicles and removed from the junction to the Seminal Vesicles. Pathology reported an epidermoid cyst. To our knowledge this is the first case of a scrotal extratesticular epidermoid cyst attached to the Seminal Vesicles. Epidermoid cysts can be seen anywhere in the midline from the cranium to the anus. Embriologically abnormal closure of neural groove or epithelial fusion lines is one of the theories that seem more probable. Genital epidermoid cysts are rare, painless and usually located in the testes. Up to date less than 10 case reports of extratesticular epidermoid cysts have been published. For those cases malignancy may not be ruled out, so the surgical removal was advocated.
Neil A Bayman - One of the best experts on this subject based on the ideXlab platform.
-
when should the Seminal Vesicles be included in the target volume in prostate radiotherapy
Clinical Oncology, 2007Co-Authors: Neil A Bayman, James P WylieAbstract:External beam radiotherapy to the prostate and Seminal Vesicles as a radical treatment for prostate cancer can result in a significant dose being delivered to the rectum. This can be reduced if the target volume includes the prostate only. Using a Medline search, published studies are reviewed to show that the risk of Seminal vesicle involvement can be accurately predicted using readily available pre-treatment parameters. We recommend when to exclude the Seminal Vesicles from a target volume, and the proportion of Seminal Vesicles that should be included in a target volume in higher risk patients.
